Brief: Chromadex Reports FDA's Conclusion That Nicotinamide Mononucleotide May Not Be Sold Or Marketed As Dietary Supplement In U.S.

Niagen Bioscience

11/11/2022 14:13

Nov 11 (Reuters) - Chromadex Corp  CDXC.O :
    * CHROMADEX REPORTS FDA’S CONCLUSION THAT NICOTINAMIDE
MONONUCLEOTIDE (NMN) MAY NOT BE SOLD OR MARKETED AS A DIETARY
SUPPLEMENT IN THE UNITED STATES
    * CHROMADEX CORP - U.S. FDA DECLARES NMN INGREDIENT MAY NOT
BE
SOLD OR MARKETED AS A DIETARY SUPPLEMENT IN U.S. SINCE FIRST
INVESTIGATED AS A DRUG

Source text for Eikon:  ID:nBw5zHhVRa 
Further company coverage:  CDXC.O 
 ((reuters.briefs@thomsonreuters.com;))